Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of NNC6019-0001 in transthyretin amyloid cardiomyopathy
2021-006226-49Phase 2Active
- Sponsor
- Novo Nordisk
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of coramitug in amyloidotic transthyretin cardiomyopathy (ATTR-CM) and amyloid cardiomyopathy (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change in 6-minute walk test distance. Started Jun 2022; status: active.
02
Drugs
coramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)amyloid cardiomyopathy
Beyond the preview
Go deeper on 2021-006226-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006226-49.